EXTON, Pa.--(BUSINESS WIRE)--BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds that there has been a slight increase in ...
Alberta, Canada becomes the latest province to begin switching patients from originator adalimumab (Humira) to biosimilar versions as part of its Biosimilars Initiative. Alberta, Canada has expanded ...
A major California health plan has struck a novel deal directly with a drug manufacturer for a cheaper version of Humira, cutting out pharmacy benefit managers — controversial middlemen in the drug ...
About 1.5 million Americans suffer from rheumatoid arthritis, a chronic disease in which the immune system attacks healthy cells, typically around the joints, causing swelling and deformity. Generally ...
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Biosimilars offer clinically effective treatment alternatives to ...
Abbott Laboratories, which received a surprisingly quick approval for its Humira rheumatoid-arthritis drug earlier this week, expects the drug to see sales of more than $150 million globally in 2003 ...
"Interchangeability would change the game for Humira," Mohan said. It also would be a game-changer for biosimilars hoping to compete in the space, as it could give the interchangeable the advantage of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results